A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation
- Resource Type
- Abstract
- Source
- In
Blood 13 November 2019 134 Supplement 1:4761-4761 - Subject
- Language
- ISSN
- 0006-4971